


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN APPLICATION UNDER 37 CFR 1.14(e)

In re Application of

Application Number

67/155943

Filed

2-16-88

Art Unit

Examiner

Paper No. 46Assistant Commissioner for Patents
Washington, DC 20231

1. ☒ I hereby request access under 37 CFR 1.14(e)(2) to the application file record of the above-identified ABANDONED Application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and is: (CHECK ONE)

☒ (A) referred to in:

United States Patent Application Publication No. _____, page _____, line _____,

United States Patent Number 5284931, column _____, line _____, or

an International Application which was filed on or after November 29, 2000 and which

designates the United States, WIPO Pub. No. _____, page _____, line _____.

☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11(b) or

1.14(e)(2)(i), i.e., Application No. _____, paper No. _____, page _____, line _____.

2. ☐ I hereby request access under 37 CFR 1.14(e)(1) to an application in which the applicant has filed an authorization to lay open the complete application to the public.

Signature

Date

Typed or printed name

FOR PTO USE ONLY

Approved by: _____

(initials)

Unit: _____



US005284931A

United States Patent [19]

Springer et al.

[11] Patent Number: **5,284,931**[45] Date of Patent: **Feb. 8, 1994****[54] INTERCELLULAR ADHESION
MOLECULES, AND THEIR BINDING
LIGANDS****[75] Inventors:** Timothy A. Springer, Newton, Mass.;
Robert Rothlein; Steven D. Marlin,
both of Danbury, Conn.; Michael L.
Dustin, University City, Mo.**[73] Assignee:** Dana Farber Cancer Institute,
Boston, Mass.**[21] Appl. No.:** 515,478**[22] Filed:** Apr. 27, 1990**Related U.S. Application Data****[63]** Continuation-in-part of Ser. No. 456,647, Dec. 22,
1989, which is a continuation-in-part of Ser. No.
45,963, May 4, 1987, which is a continuation-in-part of
Ser. No. 115,798, Nov. 2, 1987, which is a contin-
uation-in-part of Ser. No. 155,943, Feb. 16, 1988, which is
a continuation-in-part of Ser. No. 189,813, May 3, 1988,
which is a continuation-in-part of Ser. No. 250,446,
Sep. 28, 1988, which is a continuation-in-part of Ser.
No. 324,481, Mar. 16, 1989, which is a continuation-in-
part of Ser. No. 373,882, Jun. 30, 1989, which is a
continuation-in-part of Ser. No. 456,647, Dec. 22, 1989.**[51] Int. Cl.³** A61K 39/395**[52] U.S. Cl.** 424/85.8; 530/388.22;
530/395; 530/808; 530/868; 514/8**[58] Field of Search** 424/85.8, 85.91;
530/387, 389, 808, 388.22**[56] References Cited****PUBLICATIONS**

Cunningham C; et al., *TIBTECH* 10, Apr., 1992. "Anti-
body engineering—how to be human."
Dantel, J., et al., *Curr. Opin. Immunol.* 3:740-747
(1991), "Use of Monoclonal antibodies in human trans-
plantation,"
Flavin, T., et al., *Transpl. Proc.* 23(1):533-534 (Feb.
1991) "Monoclonal antibodies against intercellular ad-
hesion molecule 1 prolong carotid allograft survival in
CY momolgus monkeys."
Gibbs, W. W., *Scientific American* (Jul. 1993), "Try,
try again," pp. 101-103.

Hams, W. J., et al. *Tibtech* 11 (Feb. 1993), pp. 42-44.
"Therapeutic antibodies—the coming of age."
Haug, C. E., et al., *Transplantation* 55:766-773, (Apr.
1993), "A Phase I trial of immunosuppression with
anti-, cam-12 (CD54) m Ab in renal allograft recipi-
ents."

Ortho Multicenter Transplant Study Group, *New Engl.
J. Med.* 313:337-341 (Aug. 8, 1985).

Physician's Desk Reference (1993), pp. 1702-1703. "Or-
thoclone OKT3".

Marlin, S. D. et al. 1987. *Cell* 51: 813-819. "Purified
Intercellular Adhesion Molecule-1 . . ."

Rothlein, R. et al. 1986. *J. Immunol.* 137:1270-1274. "A
Human Intercellular Adhesion Molecule (ICAM-1) . . ."

Dustin, M. L. et al. 1986. *J. Immunol.* 137(1):245 "In-
duction by IL1 and Interferon- γ . . ."

Cosimi et al., *J. Immunol.* 144(12):4604-4612 (1990).

Flavin et al., *Transplant. Proc.* 23(1):553-534 (1991).

Tolkoff-Rubin et al., *J. Amer. Soc. Nephrology* 2(3):820
No. 2P (1991).

Kavanaugh et al., *56th Meeting of Amer. College of
Rheumatology*, Oct. 13-15, Atlanta, Ga. (1992).

Boyd et al., *Proc. Natl. Acad. Sci. USA* 85:3095-3099
(1988).

(List continued on next page.)

Primary Examiner—Christine M. Nucker**Assistant Examiner**—Thomas Cunningham**Attorney, Agent, or Firm**—Sterne, Kessler, Goldstein &
Fox**[57]****ABSTRACT**

Pharmaceutical compositions comprising antibodies to
intercellular adhesion molecule-1 (ICAM-1 or CD54)
are useful in methods of decreasing the severity of in-
flammation associated with the adhesion of leukocytes
to cells bearing ICAM-1. Treatment with anti-ICAM-1
antibodies reduced the severity of inflammation associ-
ated with acute organ or tissue rejection and prolonged
allograft survival time. Such compositions may option-
ally contain other immunosuppressive agents.

11 Claims, 25 Drawing Sheets